메뉴 건너뛰기




Volumn 49, Issue 10, 2009, Pages 2167-2172

Pathogen reduction of fresh plasma using riboflavin and ultraviolet light: Effects on plasma coagulation proteins

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FIBRINOGEN; PLASMIN INHIBITOR; POLYMER; PROTEIN C; PROTEIN S; PROTHROMBIN; RIBOFLAVIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; VON WILLEBRAND FACTOR RISTOCETIN COFACTOR;

EID: 70350462130     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2009.02272.x     Document Type: Article
Times cited : (47)

References (41)
  • 1
    • 34250650032 scopus 로고    scopus 로고
    • Zero tolerance
    • Prowse C. Zero tolerance. Transfusion 2007 47 : 1106 9.
    • (2007) Transfusion , vol.47 , pp. 1106-1109
    • Prowse, C.1
  • 4
    • 0026669973 scopus 로고
    • Manufacture and in vitro characterization of a solvent/detergent-treated human plasma
    • Hellstern P, Sachse H, Schwinn H, Oberfrank K. Manufacture and in vitro characterization of a solvent/detergent-treated human plasma. Vox Sang 1992 63 : 178 85.
    • (1992) Vox Sang , vol.63 , pp. 178-185
    • Hellstern, P.1    Sachse, H.2    Schwinn, H.3    Oberfrank, K.4
  • 5
    • 0033485345 scopus 로고    scopus 로고
    • Solvent/detergent-treated plasma has decreased antitrypsin activity and absent antiplasmin activity
    • Mast AE, Stadanlick JE, Lockett JM, Dietzen DJ. Solvent/detergent-treated plasma has decreased antitrypsin activity and absent antiplasmin activity. Blood 1999 94 : 3922 7.
    • (1999) Blood , vol.94 , pp. 3922-3927
    • Mast, A.E.1    Stadanlick, J.E.2    Lockett, J.M.3    Dietzen, D.J.4
  • 6
    • 0035120295 scopus 로고    scopus 로고
    • A potentially improved approach to methylene blue virus inactivation of plasma: The Maco Pharma Maco-Tronic system
    • Hornsey VS, Drummond O, Young D, Docherty A, Prowse CV. A potentially improved approach to methylene blue virus inactivation of plasma: the Maco Pharma Maco-Tronic system. Transfus Med 2001 11 : 31 6.
    • (2001) Transfus Med , vol.11 , pp. 31-36
    • Hornsey, V.S.1    Drummond, O.2    Young, D.3    Docherty, A.4    Prowse, C.V.5
  • 9
    • 62349093765 scopus 로고    scopus 로고
    • Processing and components: Leucoreduction and pathogen reduction
    • In. Barbara, J.A. Regan, F.A. Contreras, M.C. editors. Cambridge. Cambridge University Press. p.
    • Cardigan R, Prowse C, Williamson LM. Processing and components: leucoreduction and pathogen reduction. In : Barbara JA, Regan FA, Contreras MC, editors. Transfusion microbiology. Cambridge : Cambridge University Press 2008. p. 239 58.
    • (2008) Transfusion Microbiology , pp. 239-258
    • Cardigan, R.1    Prowse, C.2    Williamson, L.M.3
  • 11
    • 33645289412 scopus 로고    scopus 로고
    • Functional inactivation of white blood cells by Mirasol treatment
    • Fast LD, DiLeone G, Li J, Goodrich R. Functional inactivation of white blood cells by Mirasol treatment. Transfusion 2006 46 : 642 8.
    • (2006) Transfusion , vol.46 , pp. 642-8
    • Fast, L.D.1    Dileone, G.2    Li, J.3    Goodrich, R.4
  • 13
    • 2942558817 scopus 로고    scopus 로고
    • Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light
    • Ruane PH, Edrich R, Gampp D, Keil SD, Leonard L, Goodrich RP. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004 44 : 877 85.
    • (2004) Transfusion , vol.44 , pp. 877-85
    • Ruane, P.H.1    Edrich, R.2    Gampp, D.3    Keil, S.D.4    Leonard, L.5    Goodrich, R.P.6
  • 14
    • 33748445931 scopus 로고    scopus 로고
    • The Mirasol™ PRT system for pathogen reduction of platelets and plasma: An overview of current status and future trends
    • Goodrich RP, Edrich RA, Li J, Seghatchian J. The Mirasol™ PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006 35 : 5 17.
    • (2006) Transfus Apher Sci , vol.35 , pp. 5-17
    • Goodrich, R.P.1    Edrich, R.A.2    Li, J.3    Seghatchian, J.4
  • 16
    • 40749148572 scopus 로고    scopus 로고
    • Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation
    • Reddy HL, Dayan AD, Cavagnaro J, Gad S, Li J, Goodrich RP. Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation. Transfus Med Rev 2008 22 : 133 53.
    • (2008) Transfus Med Rev , vol.22 , pp. 133-53
    • Reddy, H.L.1    Dayan, A.D.2    Cavagnaro, J.3    Gad, S.4    Li, J.5    Goodrich, R.P.6
  • 18
    • 0032569840 scopus 로고    scopus 로고
    • Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura
    • Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998 339 : 1585 94.
    • (1998) N Engl J Med , vol.339 , pp. 1585-94
    • Tsai, H.M.1    Lian, E.C.2
  • 19
    • 0019442145 scopus 로고
    • The complex multimeric structure composition of factor VIII/von Willebrand factor
    • Ruggeri ZM, Zimmerman TS. The complex multimeric structure composition of factor VIII/von Willebrand factor. Blood 1981 57 : 1140 3.
    • (1981) Blood , vol.57 , pp. 1140-3
    • Ruggeri, Z.M.1    Zimmerman, T.S.2
  • 20
    • 9644266966 scopus 로고    scopus 로고
    • Dissociation between the level of von Willebrand factor-cleaving protease activity and disease in a patient with congenital thrombotic thrombocytopenic purpura
    • Snider CE, Moore JC, Warkentin TE, Finch CN, Hayward CP, Kelton JG. Dissociation between the level of von Willebrand factor-cleaving protease activity and disease in a patient with congenital thrombotic thrombocytopenic purpura. Am J Hematol 2004 77 : 387 90.
    • (2004) Am J Hematol , vol.77 , pp. 387-90
    • Snider, C.E.1    Moore, J.C.2    Warkentin, T.E.3    Finch, C.N.4    Hayward, C.P.5    Kelton, J.G.6
  • 24
    • 0038057391 scopus 로고    scopus 로고
    • Coagulation factor content of solvent/detergent plasma compared with fresh frozen plasma
    • Doyle S, O'Brien P, Murphy K, Fleming C, O'Donnell J. Coagulation factor content of solvent/detergent plasma compared with fresh frozen plasma. Blood Coagul Fibrinolysis 2003 14 : 283 7.
    • (2003) Blood Coagul Fibrinolysis , vol.14 , pp. 283-7
    • Doyle, S.1    O'Brien, P.2    Murphy, K.3    Fleming, C.4    O'Donnell, J.5
  • 25
    • 1842715059 scopus 로고    scopus 로고
    • Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura
    • Yarranton H, Lawrie AS, Purdy G, Mackie IJ, Machin SJ. Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura. Transfus Med 2004 14 : 39 44.
    • (2004) Transfus Med , vol.14 , pp. 39-44
    • Yarranton, H.1    Lawrie, A.S.2    Purdy, G.3    MacKie, I.J.4    MacHin, S.J.5
  • 26
    • 35248876717 scopus 로고    scopus 로고
    • Impact of Triton X-100 on alpha 2-antiplasmin (SERPINF2) activity in solvent/detergent-treated plasma
    • Burnouf T, Goubran HA, Radosevich M, Sayed MA, Gorgy G, El-Ekiaby M. Impact of Triton X-100 on alpha 2-antiplasmin (SERPINF2) activity in solvent/detergent-treated plasma. Biologicals 2007 35 : 349 53.
    • (2007) Biologicals , vol.35 , pp. 349-53
    • Burnouf, T.1    Goubran, H.A.2    Radosevich, M.3    Sayed, M.A.4    Gorgy, G.5    El-Ekiaby, M.6
  • 28
    • 47249144803 scopus 로고    scopus 로고
    • Von Willebrand factor, ADAMTS13 and thrombotic thrombocytopenic purpura
    • Sadler JE. Von Willebrand factor, ADAMTS13 and thrombotic thrombocytopenic purpura. Blood 2008 112 : 11 8.
    • (2008) Blood , vol.112 , pp. 11-8
    • Sadler, J.E.1
  • 29
    • 8144222749 scopus 로고    scopus 로고
    • Cryoprecipitate prepared from plasma treated with methylene blue plus light: Increasing the fibrinogen concentration
    • Hornsey VS, Young DA, Docherty A, Hughes W, Prowse CV. Cryoprecipitate prepared from plasma treated with methylene blue plus light: increasing the fibrinogen concentration. Transfus Med 2004 14 : 369 74.
    • (2004) Transfus Med , vol.14 , pp. 369-74
    • Hornsey, V.S.1    Young, D.A.2    Docherty, A.3    Hughes, W.4    Prowse, C.V.5
  • 33
    • 70350454807 scopus 로고    scopus 로고
    • System (prt) Technology Reduction Pathogen Mirasol® G. P R. Summary Of Results From The Miracle trial [cited 2009 Jun 1]. Available from URL
    • Goodrich RP. Mirasol® pathogen reduction technology (PRT) system: summary of results from the MIRACLE trial. CaridianBCT Biotechnologies. 2009. [cited 2009 Jun 1]. Available from URL: http://www.caridianbct.com/cps/rde/xbcr/ SID-3916ADC2-1C0EF723/caridianbct/306690173-web.pdf
    • (2009) CaridianBCT Biotechnologies
  • 35
    • 13544277096 scopus 로고    scopus 로고
    • Solvent/detergent-treated plasma: Composition, efficacy and safety
    • Hellstern P. Solvent/detergent-treated plasma: composition, efficacy and safety. Curr Opin Hematol 2004 1 : 346 50.
    • (2004) Curr Opin Hematol , vol.1 , pp. 346-50
    • Hellstern, P.1
  • 36
    • 0038692734 scopus 로고    scopus 로고
    • Methylene blue-treated fresh-frozen plasma: What is its contribution to blood safety?
    • Williamson LM, Cardigan R, Prowse CV. Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety? Transfusion 2003 43 : 1322 9.
    • (2003) Transfusion , vol.43 , pp. 1322-9
    • Williamson, L.M.1    Cardigan, R.2    Prowse, C.V.3
  • 41
    • 0030012014 scopus 로고    scopus 로고
    • Plasma ascorbate protects coagulation factors against photooxidation
    • Parkkinen J, Vaaranen O, Vahtera E. Plasma ascorbate protects coagulation factors against photooxidation. Thromb Haemost 1996 75 : 292 7.
    • (1996) Thromb Haemost , vol.75 , pp. 292-7
    • Parkkinen, J.1    Vaaranen, O.2    Vahtera, E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.